What is Cerebrolysin?
Cerebrolysin is a porcine-brain-derived mixture of peptides and amino acids. In CASTA, the confirmatory combined functional outcome after acute ischemic stroke was neutral.
Biological role or research focus
Neurological clinical research.
A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
Role reference: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗
Names you may encounter
Porcine brain peptide hydrolysate
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Peptide and amino-acid mixture; not one defined molecule
- Research focus
- Neurological clinical research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Cerebrolysin FDA approved?
- No. No FDA-approved drug contains Cerebrolysin. Source ↗
- Is Cerebrolysin safe?
- Cerebrolysin is a brain-derived peptide mixture not approved in the U.S. Stroke trials found no effect on deaths, and a Cochrane review flagged a possible rise in non-fatal serious adverse events. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Cerebrolysin banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Cerebrolysin?
- Yes. Our records list 2 FDA actions naming it, most recently on November 10, 2021: FDA warning letter to a clinic-based compounder (Guyer Institute) stating Cerebrolysin had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| CASTA acute ischemic stroke trial (2012) | Human randomized trial | 1,070 patients with acute ischemic stroke. |
| CARS · upper-limb recovery (2016) | Human randomized trial | Patients receiving early rehabilitation after stroke; 208 enrolled according to the publication’s full-text record. |
| Cochrane stroke review · 2023 (2023) | Systematic review of randomized trials | Seven eligible trials with 1,773 participants; the review included a related peptide mixture, Cortexin, as well as Cerebrolysin. |
| Stroke meta-analysis · 2025 (2025) | Systematic review of randomized trials | 14 randomized trials totaling 2,884 patients with acute ischemic stroke. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
CASTA acute ischemic stroke trial
What did this publication test, and what did it find?
- Population / model
- 1,070 patients with acute ischemic stroke.
- Study design
- Randomized placebo-controlled study of intravenous treatment alongside standard care, with 90-day follow-up.
- Main finding
- The confirmatory combined functional endpoint did not show a significant benefit. A post-hoc analysis suggested a signal in more severely affected participants.
- Limits & context
- A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
Human randomized trial · 2016
CARS · upper-limb recovery
What did the rehabilitation-focused trial find?
- Population / model
- Patients receiving early rehabilitation after stroke; 208 enrolled according to the publication’s full-text record.
- Study design
- Double-blind placebo comparison; 21-day treatment and standardized rehabilitation, beginning 24–72 hours after stroke. Primary outcome: Action Research Arm Test at day 90.
- Main finding
- The reported Mann–Whitney estimator for the arm-test outcome was 0.71 (95% CI 0.63–0.79), favoring Cerebrolysin. Premature discontinuation was 3.8%.
- How to read it
- A Mann–Whitney estimator of 0.71 is not a 71% cure or a 71% reduction in disability.
- Limits & context
- The authors called this exploratory and requested larger confirmation. Rehabilitation context and an arm-function endpoint differ from mortality outcomes. Read alongside CASTA and the evidence reviews rather than selecting only a favorable result.
Systematic review of randomized trials · 2023
Cochrane stroke review · 2023
What did the broader review conclude about death and serious harms?
- Population / model
- Seven eligible trials with 1,773 participants; the review included a related peptide mixture, Cortexin, as well as Cerebrolysin.
- Study design
- Searches through May–June 2022; independent extraction, risk-of-bias assessment, and GRADE evidence ratings.
- Main finding
- All-cause mortality RR was 0.96 (95% CI 0.65–1.41). For Cerebrolysin, non-fatal serious adverse events had RR 2.39 (95% CI 1.10–5.23), while total serious events did not clearly differ.
- How to read it
- Mortality, total serious events, and non-fatal serious events are separate endpoints.
- Limits & context
- Eligibility required treatment started within 48 hours. Missing functional-outcome reporting and risk-of-bias concerns restrict conclusions. The mortality pool contains a related agent; do not attribute every pooled result exclusively to Cerebrolysin.
Systematic review of randomized trials · 2025
Stroke meta-analysis · 2025
Does a newer favorable neurological-score result resolve the debate?
- Population / model
- 14 randomized trials totaling 2,884 patients with acute ischemic stroke.
- Study design
- Pooled neurological-score changes, functional independence, mortality, and harms; RoB 2 and GRADE assessments reported.
- Main finding
- The abstract reported improved neurological-score change, but functional independence was not statistically significant: RR 1.31 (95% CI 0.90–1.91). Mortality and total serious adverse events also did not clearly differ.
- How to read it
- A score change does not establish greater independence or survival.
- Limits & context
- Review eligibility and endpoint definitions differ from Cochrane. The abstract calls hemorrhagic-transformation results nonsignificant despite a confidence interval excluding 1; that inconsistency needs full-text and statistical review. It should not be used as settled evidence of safety or benefit.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
42 registered studies name Cerebrolysin as an intervention; 6 are recruiting or under way, 3 have not started recruiting yet, 19 completed and 14 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 42 listed studies.
Search additional PubMed records ↗Risks & interactions
Cerebrolysin is a brain-derived peptide mixture not approved in the U.S. Stroke trials found no effect on deaths, and a Cochrane review flagged a possible rise in non-fatal serious adverse events.
Randomized stroke trials with over a thousand patients report safety data. A Cochrane review found no clear difference in total serious adverse events but more non-fatal serious events. Findings do not cover similarly named products.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- Possible increase in non-fatal serious adverse events in acute stroke trials (Cochrane review, moderate certainty)
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Cochrane review: Cerebrolysin for acute ischaemic stroke (2023) ↗ · CASTA acute ischemic stroke trial (2012) ↗ · CARS stroke recovery trial (2016) ↗ · Stroke meta-analysis of 14 randomized trials (2025) ↗
Safety & what remains unknown
Trial tolerability applies to the tested clinical preparation and setting. It does not verify a mixture sold under a similar name.
Evidence boundaries
A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A category lists. An FDA warning letter (2021) stated it had not been nominated for the 503A bulks list. source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; Cerebrolysin is reported to be registered as a medicine in some countries outside the US (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Cerebrolysin among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
- FDA warning letter to a clinic-based compounder (Guyer Institute) stating Cerebrolysin had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The selected study concerns adjunctive treatment after acute ischemic stroke, rather than enhancement of cognition in healthy people.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The mixture is studied for proposed neurobiological effects. A complex preparation cannot be represented by a single amino-acid sequence or atomic molecular structure.
Questions worth asking
- Can Cerebrolysin have one exact molecular diagram?
- What material, population, and route were actually studied?
- A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can Cerebrolysin have one exact molecular diagram?
No. It is a mixture, so a single atomic drawing would misrepresent the preparation.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
- PubMed · PMID 22282884 ↗
- CARS · upper-limb recovery · 2016 ↗
- Cochrane stroke review · 2023 · 2023 ↗
- Stroke meta-analysis · 2025 · 2025 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
